XFOR Form 3 — John Volpone Files Initial Statement; No Holdings

Rhea-AI Filing Summary

X4 Pharmaceuticals, Inc. (XFOR) Form 3 reports that John Volpone, listed as President and a Director, filed an initial Section 16 statement for the 08/12/2025 event. The filing states no securities are beneficially owned by the reporting person at the time of the statement. The form was signed by an attorney-in-fact on 08/14/2025 and includes an Exhibit 24 power of attorney.

Positive

• Section 16 disclosure filed for John Volpone showing regulatory compliance
• Exhibit 24 power of attorney included, indicating an authorized filing process

Negative

• No securities beneficially owned by the President/Director as of the filing date, showing no reported insider holding

Insights

Corporate Governance Analyst

TL;DR: Officer disclosure filed; reporting person holds no shares.

The filing shows John Volpone is disclosed as President and a Director of X4 Pharmaceuticals (XFOR) with an initial Form 3 dated for the 08/12/2025 event. The document explicitly states no securities are beneficially owned by him at the time of filing, which means there is no insider stock position reported on this form.

This is important for investors because insider ownership levels and subsequent transactions can signal alignment with shareholders; here, the immediate disclosure indicates compliance with Section 16 reporting but no current insider stake is recorded.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Volpone John

(Last) (First) (Middle)

C/O X4 PHARMACEUTICALS INC.

61 NORTH BEACON STREET 4TH FLOOR

(Street)

BOSTON MA 02134

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2025

3. Issuer Name and Ticker or Trading Symbol
X4 Pharmaceuticals, Inc [ XFOR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 Power of Attorney No securities are beneficially owned

No securities are beneficially owned.

	/s/ Brian Bowersox, Attorney-In-Fact	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does XFOR's Form 3 filed for John Volpone on 08/12/2025 state?

The Form 3 for John Volpone (President and Director) states that no securities are beneficially owned as of the event date 08/12/2025.

Does the filing show any derivative or common shares owned by the reporting person?

No. The filing explicitly states no securities are beneficially owned, and no entries appear in Table I or Table II.

Who signed the Form 3 for XFOR and when was it signed?

The Form 3 was signed by /s/ Brian Bowersox, Attorney-In-Fact on 08/14/2025.

What role does John Volpone have at X4 Pharmaceuticals according to the filing?

The filing lists John Volpone as President and a Director of X4 Pharmaceuticals (XFOR).

Is there any indication of an amendment to a prior Form in this filing?

No amendment date is provided; the form is an initial Form 3 filing.